{"id":58264,"date":"2023-08-21T11:13:51","date_gmt":"2023-08-21T01:13:51","guid":{"rendered":"https:\/\/hudson.org.au?post_type=hdsn_news_post&p=58264"},"modified":"2024-07-01T13:40:47","modified_gmt":"2024-07-01T03:40:47","slug":"melbourne-team-on-the-verge-of-a-more-accurate-test-for-ovarian-cancer","status":"publish","type":"hdsn_news_post","link":"https:\/\/hudson.org.au\/news\/melbourne-team-on-the-verge-of-a-more-accurate-test-for-ovarian-cancer\/","title":{"rendered":"Researchers close to a more accurate ovarian cancer test"},"content":{"rendered":"\n

A new blood test is now being developed to improve ovarian cancer<\/a> diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients and the healthcare system.<\/p>\n\n\n\n

Hudson Institute of Medical Research, funded by the Ovarian Cancer Research Foundation (OCRF)<\/a>, has developed a new diagnostic test for ovarian cancer, which is now being commercialised by ASX-bound Australian company Cleo Diagnostics Ltd.<\/a><\/p>\n\n\n\n

Cleo will advance the availability of its cancer diagnostics platform, which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening. The test will now enter a development phase and undergo validation prior to clinical use.<\/p>\n\n\n\n

Biomarker for ovarian cancer test identified <\/h2>\n\n\n\n

The blood tests will be underpinned by a patented novel biomarker, CXCL10, which is produced early and at high levels by ovarian cancers, but not in non-malignant disease. CXCL10 was first identified at Hudson Institute by Research Group Head of the Ovarian Cancer Biomarkers Research Group, Dr Andrew Stephens<\/a>, who is also now Cleo\u2019s Chief Scientific Officer.<\/p>\n\n\n\n

Initial clinical use will focus on the surgical triage market to improve treatment outcomes for patients with ovarian cancer, and simultaneously avoid unnecessary surgery and anxiety for women with far more common non-cancerous conditions. Beyond surgical triage, Cleo Diagnostics will conduct further clinical trials to evaluate the effectiveness of the underlying core technology for disease recurrence following surgery and ultimately aims to develop broader screening applications in the general population.<\/p>\n\n\n\n

Current ovarian cancer diagnosis and treatment <\/h2>\n\n\n\n

There is no accurate and reliable detection test for ovarian cancer \u2014 a pap test does not detect ovarian cancer. Ovarian cancer is the most lethal of all cancers affecting women in Australia, and a silent killer. The current five year survival rate is 49 per cent and this has not changed substantively in 50 years.<\/p>\n\n\n\n

Ovarian cancers are often indistinguishable from common, non-cancerous disease. Currently patients undergo a combined CA-125 blood test and ultrasound to provide an assessment of disease. However, neither is sufficient for an accurate diagnosis and they are only used for surgical referral. Invasive surgery to remove the ovaries remains the only way to definitively diagnose the presence of malignant disease.<\/p>\n\n\n\n

As a result, a large proportion of women experience a cancer scare, undergo unnecessary anxiety, trauma and invasive surgery due to the lack of accurate diagnostic technology.<\/p>\n\n\n\n

\n

\n Read more | <\/strong>\n The power of IFN-e: ovarian cancer breakthrough<\/a> <\/p>\n <\/div>\n\n \n\n\n

Ovarian cancer surgical triage test<\/h2>\n\n\n\n

The CLEO Surgical Triage Test is being developed as an easy to administer blood test that accurately distinguishes benign from malignant disease without surgical intervention. The potential benefits are significant<\/p>\n\n\n\n